Scynexis Inc (SCYX)

The total asset value of Scynexis Inc (SCYX) stood at $ 165 Mln as on 30-Sep-23

The share price of Scynexis Inc (SCYX) is $1.68 (NASDAQ) as of 08-Dec-2023 16:00 EST. Scynexis Inc (SCYX) has given a return of -38.15% in the last 3 years.

Scynexis Inc (SCYX) has a market capitalisation of $ 63 Mln as on 08-Dec-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Scynexis Inc (SCYX) is 0.68 times as on 08-Dec-2023, a -0.76% premium to its peers’ median range of 2.82 times.

The P/E ratio of Scynexis Inc (SCYX) is 1.13 times as on 08-Dec-2023, a -0.95% premium to its peers’ median range of 21.83 times.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Scynexis Inc (SCYX) and enter the required number of quantities and click on buy to purchase the shares of Scynexis Inc (SCYX).

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

The CEO & director of Dr. Marco Taglietti M.D.. is Scynexis Inc (SCYX), and CFO & Sr. VP is Mr. David Gonzalez Angulo M.D..

The promoters of Scynexis Inc (SCYX) have pledged 0% of the total equity as on Sep-23.

Some of the close peers are:

Yes, TTM profit after tax of Scynexis Inc (SCYX) was $211 Mln.